Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

- 27/05/2019

Ghent, Belgium: 27 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces the presentation of the positive results from the first-in-human single dose DSR proof-of-concept study for volume overload due to heart failure. The investigator-initiated study was conducted by Dr. Jeffrey Testani of Yale University. The study demonstrated that single dose DSR therapy in humans was safe and well-tolerated and resulted in a clinically relevant removal of sodium with consistent results between treated patients.

More info on Sequana’s website.